

## Protein corona sensor array detects breast and prostate cancers

Luca Digiacomo,<sup>1#</sup> Kouros Jafari-Khouzani,<sup>2#</sup> Sara Palchetti,<sup>1</sup> Daniela Pozzi, Anna Laura Capriotti,<sup>3</sup>  
Aldo Laganà,<sup>3</sup> Riccardo Zenezini Chiozzi,<sup>4,5</sup> Damiano Caputo,<sup>6</sup> Chiara Cascone,<sup>6</sup> Roberto Coppola,<sup>6</sup>  
Gerardo Flammia,<sup>7</sup> Vittorio Altomare,<sup>8</sup> Antonella Grasso,<sup>8</sup> Morteza Mahmoudi<sup>9\*</sup>, Giulio Caracciolo\*

<sup>1</sup>Department of Molecular Medicine, "Sapienza" University of Rome, Viale Regina Elena 291, 00161 Rome, Italy

<sup>2</sup>IBM Watson Health, Cambridge, MA, United States

<sup>3</sup>Department of Chemistry, "Sapienza" University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy

<sup>4</sup>Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

<sup>5</sup>Netherlands Proteomics Centre, Utrecht, The Netherlands

<sup>6</sup>Department of General Surgery, University Campus-Biomedico di Roma, Via Alvaro del Portillo 200, 00128 Rome, Italy

<sup>7</sup>Department of Urology, University Campus Bio-Medico di Roma, Via Alvaro del Portillo, 200, 00128 Rome, Italy

<sup>8</sup>Breast Unit, University Campus Bio-Medico di Roma, Via Alvaro del Portillo, 200, 00128 Rome, Italy

<sup>9</sup>Precision Health Medicine, Department of Radiology Michigan State University, MI, United States

# equal contribution

\* corresponding authors: [mahmou22@msu.edu](mailto:mahmou22@msu.edu); [giulio.caracciolo@uniroma1.it](mailto:giulio.caracciolo@uniroma1.it)

	<b>Healthy (N=5)</b>
<b>Age, years</b>	
Median (range)	66 (43 – 69)
<b>Sex, n (%)</b>	
Male	2 (40%)
Female	3 (60%)
<b>Comorbidity</b>	
None	1 (20%)
Hypertension	4 (80%)
Diabetes mellitus	1 (20%)
Hypothyroidism	1 (20%)
Neurologic disorders	0 (0%)
Cholelithiasis	2 (40%)
Diverticular disease	3 (60%)


**Table S1.** Demographic and clinic characteristics of healthy controls.

	<b>Breast cancer (N=8)</b>
<b>Age, years</b>	
Median (range)	68 (41 - 85)
<b>Sex, n (%)</b>	
Male, n (%)	0 (0%)
Female, n (%)	8 (100%)
<b>Comorbidity</b>	
None	4 (50%)
Hypertension	3 (37.5%)
Diabetes mellitus	0 (0%)
Hypothyroidism	2 (25%)
Neurologic disorders	2 (25%)
<b>Stage TNM</b>	
0	1 (12.5%)
Ia	2 (25%)
Ib	0
IIa	2 (25%)
IIb	2 (25%)
IIIa	1 (12.5%)
IIIb	0
IIIc	0
IV	0

**Table S2.** Demographic and clinical characteristics of breast cancer patients.

	<b>Prostate cancer (N=8)</b>
<b>Age, years</b>	
Median (range)	66.5 (63 – 76)
<b>Sex, n (%)</b>	
Male, n (%)	8 (100%)
<b>Comorbidity</b>	
None	5 (62.5%)
Hypertension	3 (37.5%)
Diabetes mellitus	1 (12.5%)
Hypothyroidism	0 (0%)
Neurologic disorders	0 (0%)
<b>Stage TNM</b>	
I	0 (0%)
II	3 (37.5%)
III	3 (37.5%)
IV	2 (25%)

**Table S3.** Demographic and clinical characteristics of prostate cancer patients.



**Fig. S1.** Venn diagrams reporting the number of proteins validated onto the surface of L1, L2 and L3 liposomes after 1-hour incubation with human plasma from healthy subjects and from patients with breast and prostate cancers.